CD68, generally represented macrophages and associated with a lower complete remission in AML (Liu et al., 2022), were also found to be higher in UNC93B1-high expressed AML patients (r = 0.618, p < 0.001, Figure 5C), which further validated the role of innate immune cells in AML pathogenesis and therapy response. The gene discussed is CD68; the disease is acute myeloid leukemia.